Drug intelligence / Profile preview

mixed protamine human insulin injection 30R

Development stage
Unknown
Lead developer
Gan & Lee Pharmaceuticals
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

**Similin 30** is Gan & Lee's premixed recombinant human insulin product for diabetes mellitus. It contains 30% soluble human insulin for relatively rapid prandial insulin activity and 70% protamine human insulin for intermediate-duration basal insulin activity. The biphasic formulation activates the insulin receptor to promote peripheral glucose uptake and suppress hepatic glucose output; it is supplied as a 100 units/mL injectable suspension for subcutaneous use and is approved in China for people with diabetes, including adults with type 1 or type 2 diabetes. ([ganleediabetes.com](https://www.ganleediabetes.com/insulin/12.html))

Brand names
Similin 30Similin30Similin-30普秀霖30
Other names
Mixed Protamine Recombinant Human Insulin Injection 30RMixed Protamine Human Insulin Injection 30R精蛋白人胰岛素混合注射液30R
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on mixed protamine human insulin injection 30R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mixed protamine human insulin injection 30R.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call